Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Accumulated Expenses (2021 - 2025)

Prime Medicine filings provide 5 years of Accumulated Expenses readings, the most recent being $12.6 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 20.77% to $12.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.6 million, a 20.77% decrease, with the full-year FY2025 number at $12.6 million, down 20.77% from a year prior.
  • Accumulated Expenses hit $12.6 million in Q4 2025 for Prime Medicine, up from $11.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $37.2 million in Q4 2021 to a low of $300000.0 in Q2 2023.
  • Median Accumulated Expenses over the past 5 years was $11.0 million (2025), compared with a mean of $12.6 million.
  • Biggest five-year swings in Accumulated Expenses: plummeted 71.26% in 2022 and later soared 3531.67% in 2024.
  • Prime Medicine's Accumulated Expenses stood at $37.2 million in 2021, then plummeted by 71.26% to $10.7 million in 2022, then skyrocketed by 32.02% to $14.1 million in 2023, then increased by 12.71% to $15.9 million in 2024, then dropped by 20.77% to $12.6 million in 2025.
  • The last three reported values for Accumulated Expenses were $12.6 million (Q4 2025), $11.0 million (Q3 2025), and $12.2 million (Q2 2025) per Business Quant data.